AstraZeneca PLC (AZN)
NASDAQ: AZN · Real-Time Price · USD
94.39
+0.40 (0.43%)
At close: Jan 16, 2026, 4:00 PM EST
94.75
+0.36 (0.38%)
After-hours: Jan 16, 2026, 7:58 PM EST
AstraZeneca Revenue
AstraZeneca had revenue of $15.19B in the quarter ending September 30, 2025, with 11.99% growth. This brings the company's revenue in the last twelve months to $58.13B, up 13.52% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$58.13B
Revenue Growth
+13.52%
P/S Ratio
5.02
Revenue / Employee
$625,694
Employees
92,900
Market Cap
291.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | 24.38B | 2.29B | 10.38% |
| Dec 31, 2018 | 22.09B | -375.00M | -1.67% |
| Dec 31, 2017 | 22.47B | -537.00M | -2.33% |
| Dec 31, 2016 | 23.00B | -1.71B | -6.90% |
| Dec 31, 2015 | 24.71B | -1.84B | -6.93% |
| Dec 31, 2014 | 26.55B | 741.00M | 2.87% |
| Dec 31, 2013 | 25.81B | -2.17B | -7.75% |
| Dec 31, 2012 | 27.97B | -5.62B | -16.72% |
| Dec 31, 2011 | 33.59B | 787.00M | 2.40% |
| Dec 31, 2009 | 32.80B | 1.20B | 3.81% |
| Dec 31, 2008 | 31.60B | 2.04B | 6.91% |
| Dec 31, 2007 | 29.56B | 3.08B | 11.65% |
| Dec 31, 2006 | 26.48B | 2.53B | 10.54% |
| Dec 31, 2005 | 23.95B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
| Abbott Laboratories | 43.84B |
AZN News
- 3 days ago - Pharma sector doubles down on AI amid hopes of slashing costs, timelines - Reuters
- 5 days ago - AstraZeneca PLC (AZN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 5 days ago - AstraZeneca to acquire Modella AI to speed oncology drug research - Reuters
- 5 days ago - Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale - Business Wire
- 8 days ago - AstraZeneca: Oncology Dominance Justifies New All-Time Highs - Seeking Alpha
- 9 days ago - Healthy Returns: What to expect from pharma at the JPM conference - CNBC
- 11 days ago - AstraZeneca names Rick Suarez head of US biopharmaceuticals unit - Reuters
- 11 days ago - Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit - Business Wire